Table 2.

Associations between polygenic scores and phenotypes.

	SCZ‐PRS			BPD‐PRS
Case/control	OR (95% CI)	R 2 [%]	P	OR (95% CI)	R 2 [%]	P
SCZ	2.00 (1.85–2.16)	4.67	1.4 × 10−67	1.73 (1.44–2.08)	0.53	4.4 × 10−9
BPD	1.35 (1.26–1.44)	0.92	4.8 × 10−19	2.00 (1.71–2.33)	0.90	1.3× 10−18
Alcohol UD	1.19 (1.16–1.22)	0.57	5.3 × 10−50	1.18 (1.12–1.24)	0.09	1.7 × 10−9
Amphetamine UD	1.27 (1.21–1.33)	0.67	7.3 × 10−25	1.07 (0.97–1.18)	0.01	0.185
Cocaine UD	1.29 (1.20–1.39)	0.62	8.2 × 10−12	1.13 (0.95–1.34)	0.03	0.159
Cannabis UD	1.23 (1.18–1.29)	0.49	1.1 × 10−19	1.14 (1.03–1.26)	0.04	0.011
Opioid UD	1.27 (1.17–1.38)	0.54	7.8 × 10−9	1.24 (1.03–1.50)	0.08	0.024
Sedative UD	1.31 (1.25–1.37)	0.89	9.8 × 10−30	1.29 (1.15–1.44)	0.14	5.9 × 10−6
EO	1.23 (1.18–1.28)	0.54	7.7 × 10−24	1.16 (1.06–1.27)	0.05	1.9 × 10−3
Ever‐smoking versus never‐smoking	1.07 (1.05–1.09)	0.19	1.5 × 10−12	1.00 (0.98–1.02)	<0.01	0.917
Quantitative	β (95% CI)	R 2 [%]	P	β (95% CI)	R 2 [%]	P
FTND	0.16 (0.09–0.22)	0.56	1.4 × 10−6	0.26 (0.11–0.41)	0.27	7.9 × 10−4
CPD	0.24 (0.15–0.33)	0.08	1.8 × 10−7	0.20 (−0.01–0.41)	0.01	0.056
Number of admissions	0.26 (0.17–0.35)	0.35	4.7 × 10−9	0.09 (−0.12–0.30)	0.01	0.403

To account for multiple testing, the significance level was set to 0.05/20 = 2.5 × 10⁻³. BPD, bipolar disorder; CPD, cigarettes per day; EO, early onset of addiction as assessed by admission to in‐patient addiction treatment before reaching the age of 26 years; FTND, Fagerström Test of nicotine dependence; PRS, polygenic risk scores; UD, use disorder; SCZ, schizophrenia. Ever‐smoking was assessed by ever smokers against never smokers. The estimate for CPD corresponds to number of cigarettes. To facilitate comparison of effects, the PRSs were scaled to give an OR of 2 for their corresponding disorder.